| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DYN | Common Stock | Options Exercise | $382 K | +68.9 K | +56.51% | $5.54 | 191 K | Mar 8, 2024 | Direct | |
| transaction | DYN | Common Stock | Options Exercise | $96 K | +17.3 K | +9.08% | $5.54 | 208 K | Mar 8, 2024 | Direct | |
| transaction | DYN | Common Stock | Sale | -$778 K | -30.8 K | -14.77% | $25.31 | 177 K | Mar 8, 2024 | Direct | F1 |
| transaction | DYN | Common Stock | Sale | -$1.48 M | -55.2 K | -31.11% | $26.72 | 122 K | Mar 8, 2024 | Direct | F2 |
| transaction | DYN | Common Stock | Sale | -$7.9 K | -289 | -0.24% | $27.33 | 122 K | Mar 8, 2024 | Direct | F3 |
| transaction | DYN | Common Stock | Sale | -$27.8 K | -1.08 K | -0.89% | $25.70 | 121 K | Mar 11, 2024 | Direct | F4, F5 |
| transaction | DYN | Common Stock | Sale | -$39.7 K | -1.59 K | -1.32% | $24.99 | 119 K | Mar 11, 2024 | Direct | F6, F7, F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DYN | Stock option (right to buy) | Options Exercise | $0 | -68.9 K | -87.49% | $0.00 | 9.86 K | Mar 8, 2024 | Common Stock | 68.9 K | $5.54 | Direct | F9 |
| transaction | DYN | Stock option (right to buy) | Options Exercise | $0 | -17.3 K | -100% | $0.00 | 0 | Mar 8, 2024 | Common Stock | 17.3 K | $5.54 | Direct | F10 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive. |
| F4 | Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. |
| F6 | The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive. |
| F8 | Includes 115,624 unvested RSUs. |
| F9 | The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020. |
| F10 | The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |